Neuroendocrine Carcinoma Clinical Trial
Official title:
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine tumors. Patients with neuroendocrine tumors will be imaged with this agent and it will be compared to conventional imaging methods to determine the safety and efficacy of this radiopharmaceutical.
Status | Not yet recruiting |
Enrollment | 250 |
Est. completion date | |
Est. primary completion date | March 2019 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Known diagnosis of neuroendocrine tumor or suspected SSTR positive tumors by 111In-Octreotide scan, 18FDG-PET, or MRI of the abdomen where clinically indicated - At least 18 years of age - Able to provide informed consent - Karnofsky performance score greater than 50 - Females of childbearing potential must have a negative pregnancy test at screening/baseline Exclusion Criteria: - Serum creatinine > 2.0 mg/dL - Hepatic enzyme levels more than 3 times upper limit of normal - Known severe allergy or hypersensitivity to IV radiographic contrast - Use of any other investigational product or device within 30 days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessments - Patients with a body weight of 400 pounds or more or not able to enter the bore of the PET/CT scanner due to BMI, because of the compromise in image quality with CT, PET/CT, and MRI that will result - Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.) - Inability to complete the needed investigational standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) - Recognized concurrent active infection - Previous systemic or radiation treatment for another cancer of any type within the last 2 years - Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
United States | Ochsner Medical Center - Kenner | Kenner | Louisiana |
Lead Sponsor | Collaborator |
---|---|
Ochsner Health System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants with Adverse Events as a Measure of Safety and Tolerability | 5 years | Yes | |
Secondary | Number of lesions detected by 68Ga-DOTATATE compared to conventional imaging techniques | 5 years | No | |
Secondary | We want to determine if the 68Ga-DOTATATE PET Scan changes care plans compared to conventional imaging/diagnostic techniques (Octreoscan, MRI, CT) | 5 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01642251 -
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04069299 -
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
|
||
Recruiting |
NCT04464122 -
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
|
||
Recruiting |
NCT04325425 -
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
|
Phase 2 | |
Completed |
NCT03834701 -
Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms
|
N/A | |
Recruiting |
NCT03279614 -
Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
|
Phase 2 | |
Recruiting |
NCT05978284 -
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05076786 -
Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma
|
Phase 2 | |
Completed |
NCT00388063 -
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
|
Phase 2 | |
Withdrawn |
NCT03901378 -
Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
|
Phase 2 | |
Recruiting |
NCT02970786 -
Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans
|
Phase 1 | |
Completed |
NCT00663429 -
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma
|
Phase 2 | |
Recruiting |
NCT05113355 -
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
|
Phase 2 | |
Completed |
NCT03278405 -
Avelumab in G3 NEC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03837977 -
Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma
|
Phase 2 | |
Recruiting |
NCT06372626 -
Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06333314 -
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
|
Phase 2 | |
Active, not recruiting |
NCT02687958 -
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
|
Phase 2 | |
Completed |
NCT01121939 -
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
|
Phase 2 | |
Recruiting |
NCT03168607 -
Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
|
Phase 2 |